GlassScriptPhysician profile
Mia L Ryckman
NPI 1417591348
$6,257.55
in general payments reported to CMS, 2019-2025
32 companies · $1,564 in 2025
The $1,564 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,180 · 2022: $839 · 2023: $1,193 · 2024: $1,482 · 2025: $1,564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,198 · Education: $39.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,198.21 |
| Education | $39.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,552.19 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $714.00 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Janssen Biotech, INC. | $399.15 | 2021-2025 | Tremfya, Stelara, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $372.34 | 2021-2025 | Entyvio, Eohilia |
| Ardelyx, INC. | $355.80 | 2022-2025 | Ibsrela |
| Ferring Pharmaceuticals INC. | $280.66 | 2021-2024 | Rebyota |
| Pfizer INC. | $271.99 | 2022-2025 | |
| Gilead Sciences, INC. | $248.96 | 2021-2025 | Epclusa |
| Nestle Healthcare Nutrition INC. | $189.68 | 2021-2023 | |
| Redhill Biopharma INC. | $183.04 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $153.14 | 2022-2025 | Ocaliva |
| Qol Medical, LLC | $134.63 | 2023-2024 | Sucraid, Sucraid |
| Celgene Corporation | $127.46 | 2021-2024 | Zeposia |
| Lilly USA, LLC | $127.29 | 2024-2025 | Omvoh |
| Alnylam Pharmaceuticals INC. | $121.82 | 2023 | Givlaari |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $117.38 | 2021-2024 | Dificid |
| Ipsen Biopharmaceuticals, INC | $111.53 | 2024-2025 | Iqirvo |
| Aimmune Therapeutics, INC. | $96.25 | 2024-2025 | Zenpep |
| Genzyme Corporation | $82.71 | 2024-2025 | |
| Ironwood Pharmaceuticals, INC | $82.32 | 2021-2024 | Linzess |
| Madrigal Pharmaceuticals | $79.06 | 2025 | Rezdiffra |
| Braintree Laboratories, INC. | $76.97 | 2021-2025 | Suflave, Sutab |
| Regeneron Healthcare Solutions, INC. | $73.97 | 2022-2025 | Dupixent |
| Celltrion USA INC. | $72.44 | 2023-2025 | Yuflyma, Vegzelma |
| Phathom Pharmaceuticals, INC. | $61.87 | 2023-2024 | Voquezna |
| Novo Nordisk INC | $42.83 | 2025 | Wegovy |
| Daiichi Sankyo INC. | $29.55 | 2023 | Injectafer |
| Digestive Care, INC. | $24.73 | 2023 | Pertzye |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.46 | 2023 | Cyltezo |
| Oxford Immunotec USA INC | $18.48 | 2022 | |
| Evoke Pharma, INC. | $17.07 | 2025 | |
| Medtronic, INC. | $13.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mia Ryckman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.